Patents Assigned to ChronTech Pharma AB
-
Patent number: 8883169Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.Type: GrantFiled: July 7, 2011Date of Patent: November 11, 2014Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Jonas Soderholm, Lars Frelin
-
Publication number: 20140286985Abstract: Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein.Type: ApplicationFiled: March 21, 2014Publication date: September 25, 2014Applicant: ChronTech Pharma ABInventors: Matti Sallberg, Lars Frelin, Magnus Johansson
-
Publication number: 20140121587Abstract: Several needle assemblies and intracellular delivery devices that are used for the delivery of prophylactic and/or therapeutic material (i.e., delivered agents) into a tissue of a subject are disclosed. Preferably, the needle assemblies and/or the intracellular delivery devices comprise needles and/or needle electrodes, which are disposed in an array (e.g., a Y-type array having three outer needles and a center needle), wherein each needle in the array has a closed end and a plurality of apertures along each needle barrel, and the apertures on the needle barrels of the outer needles of the array are positioned to deliver the delivered agent toward the apertures of the center needle and/or an adjacent needle, but not outside of the active zone defined by the area within the needle array and the apertures on the needle barrel of the center needle are positioned to deliver the delivered agent toward the outer needles.Type: ApplicationFiled: June 13, 2012Publication date: May 1, 2014Applicant: CHRONTECH PHARMA ABInventors: Matti Sallberg, Lars Frelin
-
Patent number: 8658179Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.Type: GrantFiled: October 17, 2012Date of Patent: February 25, 2014Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
-
Publication number: 20130202554Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.Type: ApplicationFiled: April 3, 2013Publication date: August 8, 2013Applicant: CHRONTECH PHARMA ABInventor: CHRONTECH PHARMA AB
-
Patent number: 8445663Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.Type: GrantFiled: January 29, 2010Date of Patent: May 21, 2013Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Lars Frelin
-
Publication number: 20130041131Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.Type: ApplicationFiled: October 17, 2012Publication date: February 14, 2013Applicant: CHRONTECH PHARMA ABInventor: ChronTech Pharma AB
-
Publication number: 20130011375Abstract: The present invention relates generally to the field of immunology. More particularly, aspects of the invention concern the discovery of several T cell receptors (TCRs) that are specific for an immunodominant CTL epitope of hepatitis C virus (HCV). Embodiments include TCRs, DNAs encoding TCRs, methods of making TCRs, and methods of using TCRs to treat, prevent or inhibit hepatitis C virus (HCV) proliferation.Type: ApplicationFiled: November 23, 2010Publication date: January 10, 2013Applicant: CHRONTECH PHARMA ABInventor: Margaret Sällberg Chen
-
Publication number: 20130012865Abstract: A needle device for the delivery of therapeutic material into tissue comprising a connection to a pressure generation element, a lumen adapted for the passage of a therapeutic material, and a needle barrel, wherein each needle barrel comprises an opening adapted to control and deliver a pressure transmitted from the pressure generation element into a tissue to cause an increase in the permeability of a cell membrane to the therapeutic material.Type: ApplicationFiled: December 14, 2010Publication date: January 10, 2013Applicant: CHRONTECH PHARMA ABInventors: Matti Sällberg, Lars Frelin
-
Patent number: 8303956Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.Type: GrantFiled: March 26, 2010Date of Patent: November 6, 2012Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
-
Patent number: 8258275Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.Type: GrantFiled: January 19, 2011Date of Patent: September 4, 2012Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Jonas Soderholm, Lars Frelin
-
Publication number: 20120208870Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: ApplicationFiled: April 6, 2012Publication date: August 16, 2012Applicant: CHRONTECH PHARMA ABInventor: Matti Sallberg
-
Patent number: 8163712Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: GrantFiled: September 29, 2010Date of Patent: April 24, 2012Assignee: Chrontech Pharma ABInventor: Matti Sallberg
-
Patent number: 8163547Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: GrantFiled: September 29, 2010Date of Patent: April 24, 2012Assignee: Chrontech Pharma ABInventor: Matti Sallberg
-
Patent number: 8158602Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: GrantFiled: September 29, 2010Date of Patent: April 17, 2012Assignee: Chrontech Pharma ABInventor: Matti Sallberg
-
Publication number: 20120039842Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.Type: ApplicationFiled: January 29, 2010Publication date: February 16, 2012Applicant: CHRONTECH PHARMA ABInventors: Matti Sallberg, Lars Frelin
-
Publication number: 20120010394Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.Type: ApplicationFiled: July 7, 2011Publication date: January 12, 2012Applicant: CHRONTECH PHARMA ABInventors: Matti Sällberg, Jonas Soderholm, Lars Frelin
-
Patent number: 8071561Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.Type: GrantFiled: August 15, 2008Date of Patent: December 6, 2011Assignee: ChronTech Pharma ABInventors: Matti Sallberg, Jonas Soderholm, Lars Frelin
-
Patent number: 7968697Abstract: The creation of mutant hepatitis C virus (HCV) NS3/4A genes encoding proteins with altered protease activity is disclosed. Embodiments include these NS3/4A genes, HCV peptides encoded by these nucleic acids, nucleic acids encoding these HCV peptides, antibodies directed to these peptides, compositions containing these nucleic acids and peptides, as well as methods of making and using these compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: GrantFiled: May 24, 2006Date of Patent: June 28, 2011Assignee: ChronTech Pharma ABInventor: Matti Sällberg
-
Publication number: 20110150922Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.Type: ApplicationFiled: January 19, 2011Publication date: June 23, 2011Applicant: ChronTech Pharma ABInventors: Matti Sällberg, Jonas Soderholm, Lars Frelin